XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Mixed Annual Results And Strong Recent Share Returns
Why Bayer (XTRA:BAYN) Is Drawing Investor Attention Now
Bayer (XTRA:BAYN) has been on many investors’ radar after a mixed set of figures, with full year revenue of €45.9b alongside a net loss of €198m. This has prompted fresh interest in how the share price reflects this profile.
See our latest analysis for Bayer.
The mixed full year figures arrive after a 90 day share price return of 38.83% and a 1 year total shareholder return of 93.07%. The 7 day share price return of 6.83% and 30 day...